← Back to Home

Targeting Resistance to Cancer Immunotherapy, Mondego’s Oral Drug Enters First Human Trial

MB-388 aims to improve treatment responses by acting on both tumor and immune cells. The initial study will assess safety and drug activity in healthy volunteers. Whether it can help cancer patients still requires validation in subsequent clinical trials.

By SURL BioNews

Cancer immunotherapy aims to help the immune system recognize and attack tumors again, but addressing treatments that fail to work or gradually lose effectiveness remains a challenge in drug development. Portuguese biotechnology company Mondego Bio announced on November 5 that MB-388, an oral drug candidate developed to address this problem, has entered its first human trial, beginning an assessment of whether its effects can be achieved safely in humans.

The Phase 1a study involves healthy volunteers and uses a randomized, double-blind, placebo-controlled design, with progressively increasing single and multiple doses. The study focuses on safety, tolerability, and pharmacokinetics—the changes in drug concentrations after administration. The team will also use blood biomarkers to determine whether the intended pathways are affected.

MB-388 inhibits both PTPN2 and PTPN1, two protein tyrosine phosphatases. According to the company, the development strategy is to modulate signaling in tumor and immune cells, improve interferon-γ-related responses and antigen presentation, and enhance immune cell function. This proposed mechanism is intended to overcome resistance to immunotherapy, but no patient efficacy data currently support it.

For oral drugs of this kind, another key question is whether sufficient activity can be achieved within a safe range: adequate drug exposure must be maintained to potentially sustain effects on the targets. If the drug is to be combined with immune checkpoint inhibitors in the future, the tolerability of the combination will also need to be established separately. A healthy volunteer study can provide early evidence, but it cannot directly answer whether tumors will shrink.

Mondego plans to begin a Phase 1b study in January 2027, enrolling patients with advanced solid tumors whose disease has progressed during or after standard treatment, including those previously treated with immune checkpoint inhibitors. The study will first test MB-388 alone. Once initial doses have passed safety assessments, combination treatment that blocks PD-1 or PD-L1 will be added.

According to the company’s timeline, initial human pharmacokinetic and pharmacodynamic data are expected in December 2026, while results from the combination dose-escalation study are planned for release in December 2027. These are development expectations, and actual progress will depend on safety and other findings during the trials.

The information currently available for verification comes primarily from the company’s announcement, with no human results yet available for assessment. MB-388’s entry into clinical development marks the start of collecting measured human data on drug exposure, signals of activity, and tolerability. Whether it can reverse resistance to immunotherapy must await answers from trials in cancer patients.

References

  1. Mondego Bio / BioSpace